Biomarker Enrichment

Risks & contraindications

Evidence quality

Other

Highlighted claims

• The cardiac biomarker criterion is NT-proBNP greater than 800 ng/L or BNP greater than 90 ng/L. — Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU)
• The renal criterion is eGFR between 25 and 90 mL/min/1.73 m² using the CKD-EPI formula. — Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU)
• Eligible participants must meet at least one biomarker-based risk criterion at randomisation. — Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU)
• The trial uses elevated cardiac or renal biomarkers to identify ICU discharge patients at particularly high risk of poor outcomes. — Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU)
• Biomarker enrichment is intended to increase trial efficiency and relevance by selecting patients with higher event risk or greater likelihood of response. — Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU)